Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

An international view on the current approaches to frontline chronic lymphocytic leukemia therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAhmad AlhuraijiYGYeow Tee GohSOStephen Opat

Discussion

Loading...

Member takes

Overview

Expert panel recommends tailored therapy for chronic lymphocytic leukemia, emphasizing targeted therapies and risk stratification.

Key Points

  • Therapy selection considers patient preferences and disease-related factors like TP53 mutations.
  • Experts recommend targeted therapies like venetoclax and obinutuzumab for chronic lymphocytic leukemia.
  • Molecular testing and risk stratification are critical for determining the appropriate treatment course.
  • Individualized treatment strategies may differ across regions, influenced by access to novel therapies.

Cite This Study

Alhuraiji et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5cchttps://doi.org/10.1182/blood-2025-7937
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.2025
  2. 2Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma2025
  3. 3Recent Developments in Chronic Lymphocytic Leukaemia Research: Interview with an Expert2025
  4. 4Consensus on optimal use of fixed-duration BTK inhibitor and venetoclax therapy in CLL: A delphi study comparing human expertise and AI methodologies2025
  5. 5Front-line Treatment for Chronic Lymphocytic Leukemia in 2025: Finite Duration Versus Continuous Treatment2025